Panacea Biotec up over 4 pc on USFDA nod for Prasugrel tablets

Shares of Panacea Biotec today

rose by over 4 per cent after the company said it has received

final approval from the US health regulator to launch generic

Prasugrel tablets, used for preventing blood clots in people

with acute coronary syndrome, in the American market.

The stock gained 4.21 per cent to close at Rs 248.95 on

BSE. During the day, it zoomed 15.48 per cent to Rs 275.90.

On NSE, shares of the company rose 4.25 per cent to end

at Rs 247.35.

In terms of equity volume, 2.54 lakh shares of the

company were traded on BSE and over 13 lakh shares changed

hands on NSE during the day.

"The company's first-to-file abbreviated new drug

application (ANDA) of Prasugrel 5 mg and 10 mg tablets has

been approved by the US Food and Drug Administration (USFDA),"

Panacea Biotec said in a BSE filing.

The tablets are generic version of Eli Lilly's Effient

tablets, it added.

Panacea Biotec Joint MD Rajesh Jain said: "Approval and

launch of this first to file ANDA product is an important

milestone to achieve growth in our US business."

(This article has not been edited by Zeebiz editorial team and is auto-generated from an agency feed.)